Malaria is a mosquito-borne disease caused by a parasite. According to the Centers of Disease Control and Prevention, 3.4 billion people live in areas at risk of malaria transmission.
people at risk
According to the Centers of Disease Control and Prevention, 3.4 billion people live in areas at risk of malaria transmission.
The World Health Organization estimates that there were 207 million cases of malaria in 2012.
The World Health Organization estimates that there 627,000 deaths in 2012.
There are currently no licensed vaccines against malaria or any other human parasites, and resistance to anti-malarial medications is a growing problem.
The Agilvax Solution for Malaria
Agilvax has used an antibody developed against a unique blood-stage antigen to affinity-select MS2 VLPs displaying peptides from random sequence libraries. The VLPs have been tested for the ability to elicit antibodies in mice that efficiently inhibit parasite invasion of erythrocytes in vitro. These studies have led Agilvax to identify a lead vaccine candidate that shows greater than 90% inhibition in a “Growth Inhibition Assay” (GIA). Agilvax is further developing this vaccine for the prevention of malaria.